10th May 2016 08:11
LONDON (Alliance News) - Verona Pharma PLC on Tuesday said it has received positive top-line results from the phase 2a study on its RPL554 inhaler for patients with chronic obstructive pulmonary disease.
Verona said the primary and secondary objectives of the study were met, including a significant and clinically meaningful additional bronchodilation for patients in the study in addition to the standard care effects.
"The robustly positive results from this well-controlled Phase 2a trial vindicate the rationale for developing a novel bronchodilator for treatment of patients with moderate to severe disease and acute exacerbations of COPD, who will typically already be on other bronchodilators, but require additional relief," said Verona Chief Executive Jan-Anders Karlsson.
Karlsson said Verona said it now believes it has sufficient data to progress to a phase 2b clinical trial of the treatment.
Verona shares were up 5.7% to 3.83 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
VRP.L